Details of the Drug

General Information of Drug (ID: DMZJPOB)

Drug Name
MDDR 287569
Synonyms N-[1-[3-(4-Methylpiperazin-1-ylsulfonyl)propyl]piperidin-4-ylmethyl]-2,3-dihydro-1,4-benzodioxin-5-carboxamide
Indication
Disease Entry ICD 11 Status REF
Urinary incontinence MF50.2 Investigative [1]
Cross-matching ID
TTD ID
D01EAG

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 4 receptor (HTR4) TT07C3Y 5HT4R_HUMAN Modulator [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Urinary incontinence
ICD Disease Classification MF50.2
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
5-HT 4 receptor (HTR4) DTT HTR4 6.16E-01 -0.03 -0.24
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF Prostate Cancer Clinical Trials Consortium. Invest New Drugs. 2012 April; 30(2): 749-757.